Table 2.
Management of HCC recurrence.
| Time to relapse [months]; median, (range) | 11.8 (0–117.7) |
| Organs affected by recurrence | |
| Liver graft; n, (%) | 21 (45.7) |
| Extrahepatic metastases; n, (%) | 36 (78.3) |
| Lung; n, (%) | 25 (54.3) |
| Bone; n, (%) | 7 (15.2) |
| Peritoneum; n, (%) | 7 (15.2) |
| Adrenal gland; n, (%) | 5 (10.9) |
| Intra- and extrahep. recurrence; n, (%) | 11 (23.9) |
| BCLC stage | |
| A; n, (%) | 3 (6.5) |
| B; n, (%) | 5 (10.9) |
| C; n, (%) | 38 (82.6) |
| D; n, (%) | 0 (0) |
| Local treatment; n, (%) | 25 (54.3) |
| Resection; n, (%) | 15 (32.6) |
| Ablation; n, (%) | 2 (4.34) |
| TACE; n, (%) | 5 (10.8) |
| SIRT; n, (%) | 4 (8.7) |
| Systemic first-line therapy | |
| Sorafenib; n, (%) | 39 (84.8) |
| Initial dose [mg/d]; median, (range) | 400 (200–800) |
| Lenvatinib; n, (%) | 7 (15.2) |
| Initial dose [mg/d]; median, (range) | 4 (4–12) |
| Immunosuppression under first-line treatment | |
| Ciclosporin; n, (%) | 2 (4.3) |
| dose [mg/d] | 200 |
| Tacrolimus; n, (%) | 34 (73.9) |
| dose [mg/d]; median, (range) | 3 (0.5–10) |
| Sirolimus; n, (%) | 11 (23.9) |
| dose [mg/d]; median, (range) | 1 (0.5–2) |
| Everolimus; n, (%) | 19 (41.3) |
| dose [mg/d]; median, (range) | 2 (0.5–6) |
| Mycophenolat mofetil; n, (%) | 7 (15.2) |
| dose [mg/d]; median, (range) | 1000 (500–2000) |
| Dexamethason; n, (%) | 1 (2.2) |
| dose [mg/d] | 8.0 |
| Prednisolon; n, (%) | 5 (10.9) |
| dose [mg/d]; median, (range) | 5.0 (2.5–10) |
| Laboratory results at treatment initiation | |
| AFP [ng/mL]; median, (range) | 59.2 (1.0–60,500) |
BCLC: Barcelona Clinic Liver Classification; TACE: transarterial chemoembolization; SIRT: selective internal radiation therapy; AFP: alpha-fetoprotein.